Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Foghorn Therapeutics (FHTX) Other financing activities (2024)

Foghorn Therapeutics has reported Other financing activities over the past 1 years, most recently at $390000.0 for Q3 2024.

For Q3 2024, Other financing activities changed N/A year-over-year to $390000.0; the TTM value through Dec 2025 reached $390000.0, changed 0.0%, while the annual FY2024 figure was $585000.0, N/A changed from the prior year.
Other financing activities for Q3 2024 was $390000.0 at Foghorn Therapeutics.
Over five years, Other financing activities peaked at $390000.0 in Q3 2024 and troughed at $390000.0 in Q3 2024.